Maharashtra FDA asks NPPA to cap hospital consumable prices
The Maharashtra Food and Drugs Administration has written to the National Pharmaceutical Pricing Authority seeking a cap on prices of all medical and surgical consumables used in hospitals. A July survey of about 20 hospitals in the Mumbai region, Pune and Sambhaji Nagar found an IV infusion procured at ₹11.05 carrying an MRP of ₹325, a gap of 2,841%. FDA commissioner Tukaram Mundhe said patients cannot compare prices or question printed rates while receiving care.
Source
Hindustan Times — India · read the original report ↗
Desk check · compared with the source
What the desk checked (5)
- Maharashtra FDA has written to the NPPA seeking a price cap on all medical and surgical consumables in hospitals — Attributed to the FDA and an unnamed FDA official quoted in the source
- An IV infusion procured at Rs 11.05 was sold at an MRP of Rs 325, a gap of 2,841% — Figures appear in source, credited to the FDA survey of about 20 hospitals
- A syringe procured at Rs 6.75 carried an MRP of Rs 57.20 and a catheter procured at Rs 29.41 an MRP of Rs 310 — Figures appear in source as FDA survey findings
- NPPA has fixed ceiling prices for 928 scheduled formulations and retail prices for about 3,111 new drugs — Source attributes these figures to the NPPA website
- FDA commissioner Tukaram Mundhe's remarks on MRP being fixed upstream — Quoted from his post on X, as stated in the source
Analysts’ view opinion
This is less a crackdown than a request to plug a structural hole in India's price-control architecture. Scheduled drugs have margins fixed at every tier under the DPCO 2013, but hospital consumables sit outside that net — so however high an MRP is printed, selling within it remains legal. That is precisely why the state FDA has conceded the limits of its own jurisdiction and pushed its survey findings up to the NPPA for a central decision.
- The gap here is in policy design, not enforcement: because hospitals bill within the printed MRP, the state FDA has no legal handle to act.
- The move mainly serves out-of-pocket patients, and the commissioner's framing rests on information asymmetry — the party paying has the least ability to compare or refuse.
- The NPPA has precedent to draw on, having used Para 19 of the DPCO in the public interest for coronary stents and knee implants, the template being sought here.
- Implementation will be hard: fixing ceilings across hundreds of consumable categories, accounting for quality variation, and guarding against hospitals recovering margins through other service charges.
- This remains a recommendation from one state regulator based on a roughly 20-hospital sample; the decision rests entirely with the central authority.
What to watch — Watch whether the NPPA treats this as a Para 19 case or first asks for nationwide procurement-versus-MRP data, and how hospital associations respond.
The story establishes findings from a limited survey only — it does not show how widespread these margins are nationally, what hospitals say in their defence, or how the NPPA will respond.
Deep dive
Research brief · 8 facts · 3 dates · exam-readyThe brief
Context
The Maharashtra Food and Drugs Administration (FDA) has formally asked the National Pharmaceutical Pricing Authority (NPPA), the central drug price regulator, to cap the prices of all medical and surgical consumables used in hospitals. The request follows an FDA survey in July across about 20 hospitals in the Mumbai Metropolitan Region, Pune and Sambhaji Nagar that found large gaps between hospital procurement prices and the MRP billed to patients. Consumables such as IV infusions, syringes and catheters are not covered by ceiling prices the way scheduled drugs are under the Drugs (Prices Control) Order, 2013, so hospitals charging within the printed MRP cannot be acted against by the state FDA.
Key facts
- Maharashtra FDA has written to the NPPA seeking a price cap on all medical and surgical consumables used in hospitals.
- The FDA survey covered 20-odd hospitals in the Mumbai Metropolitan Region, Pune and Sambhaji Nagar in July this year.
- An IV infusion procured at Rs 11.05 carried a printed MRP of Rs 325 — a price gap of 2,841%.
- A syringe procured at Rs 6.75 was sold at an MRP of Rs 57.20; a catheter procured at Rs 29.41 carried an MRP of Rs 310.
- Similar gaps were found in oxygen masks, transfusion sets and syringes, described by an FDA official as an 'exorbitant and unjustifiable hike'.
- NPPA has so far fixed ceiling prices for 928 scheduled formulations and retail prices for around 3,111 new drugs.
- Using Para 19 of DPCO, 2013, NPPA has regulated prices of 106 anti-diabetic and cardiovascular drugs, coronary stents and knee implants in public interest.
- FDA commissioner Tukaram Mundhe posted on X on Tuesday that patients 'cannot compare prices, seek alternatives, or question a number printed on a box while receiving care'.
Timeline
- July this yearMaharashtra FDA conducts a survey of about 20 hospitals in the Mumbai Metropolitan Region, Pune and Sambhaji Nagar, finding wide procurement-versus-MRP gaps in consumables.
- Tuesday (as reported)FDA commissioner Tukaram Mundhe posts on X that patients bearing the cost have the least information to evaluate it.
- Following the surveyMaharashtra FDA formally writes to the NPPA asking that consumable medical and surgical kits be price-capped like scheduled drugs under DPCO, 2013.
Who has a stake
- Patients and their families — Bear the cost of consumables billed at MRP during treatment without the ability to compare prices or seek alternatives.
- Maharashtra FDA — Can act only on quality lapses or sales above MRP; lacks power to check high MRPs, so has escalated findings to the Centre.
- NPPA — Central regulator asked to extend ceiling-price powers under DPCO, 2013 to hospital consumables.
- Hospitals in MMR, Pune and Sambhaji Nagar — Surveyed entities charging MRPs far above procurement prices, though within legal limits.
- Manufacturers and distributors — MRP is 'often fixed upstream' by them, disconnected from trade price by a wide unexplained margin, per the FDA commissioner.
Why it matters
Consumables like IV sets, syringes, catheters and oxygen masks are unavoidable parts of hospital procedures, and the survey suggests patients may be paying many times the procurement cost while remaining legally unprotected because billing stays within MRP. The case highlights a regulatory gap: price control under DPCO, 2013 covers scheduled drugs and select devices, but not the broad category of hospital consumables. It also shows the limits of state drug regulators, whose powers stop at quality checks and above-MRP sales.
UPSC angle
Prelims pointers
- NPPA is an independent regulator overseeing drug pricing and affordable access to medicines.
- Drugs (Prices Control) Order (DPCO), 2013 governs ceiling prices; Schedule-I lists notified drugs.
- Para 19 of DPCO, 2013 lets NPPA fix prices in public interest — used for coronary stents and knee implants.
- NPPA has fixed ceiling prices for 928 scheduled formulations and retail prices for about 3,111 new drugs.
- Maharashtra FDA's July survey covered around 20 hospitals in MMR, Pune and Sambhaji Nagar.
- Maharashtra FDA commissioner: Tukaram Mundhe.
Mains framing
The Maharashtra FDA's letter to the NPPA exposes a structural asymmetry in India's health pricing regime: while scheduled drugs have fixed prices and margins at every level from stockist to retailer under DPCO, 2013, medical and surgical consumables are left to manufacturer-set MRPs. The state survey found an IV infusion procured at Rs 11.05 billed at an MRP of Rs 325 (a 2,841% gap), with comparable gaps for syringes and catheters, yet no enforcement is possible because hospitals bill within MRP — the state regulator's mandate extends only to quality and above-MRP sales. The deeper problem is informational: as the FDA commissioner notes, hospital consumables are not elective purchases, patients cannot compare prices or seek alternatives mid-treatment, so the party bearing the cost has the least ability to evaluate it. The way forward suggested by the state is to bring consumable kits under ceiling-price regulation, drawing on NPPA's precedent of invoking Para 19 of DPCO, 2013 in public interest for coronary stents and knee implants, backed by continued state-level surveillance and transparent disclosure of trade price versus MRP.
Key terms
- NPPA
- National Pharmaceutical Pricing Authority — independent regulator that fixes and revises drug prices and monitors availability and compliance.
- DPCO, 2013
- Drugs (Prices Control) Order, 2013 — the order under which ceiling prices are fixed for scheduled formulations listed in Schedule-I.
- Para 19 of DPCO, 2013
- Provision allowing NPPA to regulate prices of any drug or device in public interest; used for stents, knee implants and 106 anti-diabetic/cardiovascular drugs.
- MRP
- Maximum Retail Price printed on a product; hospitals billing at MRP are legally compliant even if far above procurement cost.
- Medical and surgical consumables
- Single-use hospital items such as IV infusions, syringes, catheters, oxygen masks and transfusion sets, currently outside ceiling-price control.
- Trade price
- The procurement price at which hospitals buy consumables, which the FDA says is disconnected from MRP by a wide unexplained margin.
Practice questions
- Examine the regulatory gap between price control of scheduled drugs and hospital consumables in India. Should the NPPA extend ceiling prices to consumables?
- Discuss the division of powers between state drug regulators and the NPPA, using the Maharashtra FDA's 2025 consumables survey as an illustration.
- 'Information asymmetry makes healthcare markets fail.' Analyse this statement with reference to the pricing of medical and surgical consumables in hospitals.
Grounded only in the source report — figures and dates are the source's, not inferred.